Shares in Cipla jumped sharply by 7 per cent after the pharma major launched an anti-asthma inhaler in Germany and Sweden. the stock was last trading at Rs 564 on the Bombay Stock Exchange.
The inhaler is a generic version of GlaxoSmithKline Plc's Advair.
Noted broking firm, Emkay Global upgraded the stock to "buy" from "accumulate" with a target of 671 rupees.
Overall addressable opportunity of generic Advair is $800 million in Europe, Emkay said.
Cipla shares were trading up 7.1 percent to 566.75 rupees as of 10:02 a.m.